Skip to main content
OpenTrials
Completed

NCT Number: NCT03455569

A Dyadic Sleep Intervention for Alzheimer's Disease Patients and Their Caregivers

Studies consistently show the negative health impact of sleep problems in both Alzheimer's disease (AD) patients and their caregivers. However, only a few sleep interventions have been conducted for AD patients or their caregivers in community settings and none have addressed both members of the dyad concurrently. To fill these gaps, this study aims to develop a sleep intervention program specifically tailored for AD patient/caregiver dyads who both experience sleep difficulties.

Completed

Looking for future studies?

Notify Me

Key information

Age range

60 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of California Los Angeles, Los Angeles, California, United States

Loading trial locations.

About this study

In 2015, Americans provided 18 billion hours of unpaid care for patients with Alzheimer's disease (AD) and other dementias, with an economic value of $221 billion. This estimate may be even higher among caregivers of AD patients when they have sleep problems. In fact, the caregivers' sleep is often disturbed by nighttime sleep disturbance of AD patients, which is one of the major reasons why those patients are admitted to institutions. Due to the bidirectional nature of sleep disturbance in AD patients and their caregivers, it is critical to develop a sleep intervention program for the dyad that addresses sleep disturbance in both individuals.

Nighttime sleep disturbance in AD patients is associated with shorter survival, lower quality of life, and decreased social engagement. Poor sleep among their caregivers is associated with increased depressive symptoms, higher levels of caregiver role burden, and increased inflammation, which is known to increase risk for cardiovascular disease. Such decline in caregivers' health may then impact the quality of care for AD patients.

Behavioral sleep intervention programs for AD patients or caregivers are feasible but long-term effects on improving sleep and health remain unclear. No behavioral sleep interventions have focused on the patient-caregiver dyad, and only a few behavioral sleep intervention studies have targeted community-dwelling AD patients or caregivers. Dyad-based sleep interventions may have better effects on sleep and other health outcomes because of the influence of AD patients on their caregivers and vice versa.

The proposed intervention focuses on educating caregivers to improve their own and the patients' sleep, using behavioral sleep management techniques. This intervention builds upon a previous caregiver focus group study (VA HSR&D LIP 65-154, PI: Song) and the existing sleep interventional research studies, which included patients with mild cognitive impairments and AD patients. The sleep program involves 4 face-to-face meetings plus 1 telephone session. Phase 1 study aims to iteratively refine and finalize the intervention program materials with 5 AD patient/caregiver dyads. Phase 2 study aims to pilot test the effects of the intervention program (n=20 dyads) on sleep, health, and quality of life in both members of the group, compared to a non-directive education-only control program (n=20 dyads) in a small randomized controlled trial. Primary outcomes will include objective sleep efficiency and total wake time measured by actigraphy for AD patients and subjective sleep measured by the Pittsburgh Sleep Quality Index for caregivers. A unique aspect of the proposed study is that the program is tailored to address sleep problems of both patients and caregivers, and includes upstream biomarkers to evaluate a key mechanism of intervention benefits that can be further explored in future research.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for Alzheimer's disease (AD) patients:

  • AD diagnosis OR probable or possible AD as documented in electronic medical record, which includes Mini Mental State Exam score >12 (indicating mild to moderate severity of AD) and neuroimaging evidence
  • Community-dwelling
  • >1 sleep problem >3x/week on the Neuropsychiatric Inventory Nighttime Behavior Scale
  • Aged >60 years
  • Able to ambulate with or without assistive device
  • Have an eligible caregiver (see below)

Inclusion criteria

for caregivers:

  • Live with an eligible patient
  • Aged >21 years
  • Have regularly assisted patient with >1 of 6 basic activities of daily living (ADLs) (i.e., bathing, dressing, toileting, transfers, continence, feeding) or >1 of 8 Instrumental ADL (IADLs) (i.e., using the telephone, shopping, preparing meals, housekeeping, laundry, transportation, taking medicine, managing money) for the past 6 months
  • Pittsburgh Sleep Quality Index (PSQI) total score >5
  • Montreal Cognitive Assessment (MoCA) score >= 23
  • Can communicate in English

Exclusion criteria

  • If AD patient is bed bound

Treatment and study plan

Behavioral sleep education

Behavioral

This group will receive manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy

Education only

Behavioral

This group will receive information about sleep, aging, and dementia, but without specific or individualized recommendations

Primary outcomes

  1. Sleep efficiency for Alzheimer's disease patients

    Time frame: 3 months after the last session of the sleep intervention

    Sleep efficiency (mean percent time asleep while in bed) will be calculated from 3 days of wrist actigraphy

  2. Total wake time for Alzheimer's disease patients

    Time frame: 3 months after the last session of the sleep intervention

    Total wake time (mean total minutes awake from sleep onset to get up time) will be calculated from 3 days of wrist actigraphy

  3. Sleep quality for caregivers

    Time frame: 3 months after the last session of the sleep intervention

    Total score on the Pittsburgh Sleep Quality Index will be used as a measure of sleep quality

Secondary outcomes

  1. Cognitive function for Alzheimer's disease patients

    Time frame: 3 months after the last session of the sleep intervention

    Total score on the Alzheimer's Disease Assessment Scale-Cognitive Subscale test will be used as a measure of cognitive function

  2. Problematic behaviors for Alzheimer's disease patients

    Time frame: 3 months after the last session of the sleep intervention

    Total score on the Revised Memory and Behavior Problem Checklist will be used as a measure of problematic behaviors

  3. Depression for Alzheimer's disease patients

    Time frame: 3 months after the last session of the sleep intervention

    Total score on the Cornell Scale for Depression in Dementia will be used as a measure of depression

  4. Caregiver burden for caregivers

    Time frame: 3 months after the last session of the sleep intervention

    Total score on the Zarit Burden Interview will be used as a measure of caregiver burden

  5. Stress for caregivers

    Time frame: 3 months after the last session of the sleep intervention

    Total score on the Perceived Stress Scale will be used as a measure of stress

  6. Depression for caregivers

    Time frame: 3 months after the last session of the sleep intervention

    Total score on the Center for Epidemiological Study-Depression will be used as a measure of depression

  7. Inflammation for caregivers

    Time frame: 3 months after the last session of the sleep intervention

    Levels of C-reactive protein and gene expression of inflammation will be measured

  8. Quality of life for Alzheimer's disease patients

    Time frame: 3 months after the last session of the sleep intervention

    Total score on the Quality of Life-Alzheimer's Disease Scale will be used as a measure of quality of life

Sponsors and collaborators

Lead sponsor

University of California, Los Angeles

Other

Registry information

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Mar 6, 2018
Registry last updated
Mar 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.